As Tekmira Puts Cholesterol Rx Trial on Hold, Questions Linger Over Target

The company chalked up the setback to the performance of the lipid nanoparticle used to deliver the drug, but inhibition of the drug's target has been associated with significant side effects.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.